The drastic cost-cutting move follows the deaths of two teenagers that forced the company to restrict usage of its gene therapy for Duchenne muscular dystrophy.

Sarepta Therapeutics is facing a challenging period after the deaths of two patients who received its Columbus-invented gene therapy for Duchenne muscular dystrophy. Sarepta opens Columbus R&D center,

The company aims to focus on high-impact programmes to meet its 2027 financial obligations and support long-term viability.